• Journal of the Korean Society of Radiology
• /
• v.10 no.8
• /
• pp.619-627
• /
• 2016

The purpose of this study is to investigate the effect of CT contrast agent and MRI contrast agent on the area dose in the body when using automatic exposure control system in general radiography. After making rectangular holes in the center of the abdominal thickness paraffin phantom, CT contrast agent and MRI contrast agent were respectively diluted with physiological saline solution for contrast medium dilution ratio of 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:10%. Each experiment was set to 78 kVp, 320 mA, which is the proper condition for KUB photography, and thereafter a total of 30 inspections were made for each dilution ratio using an automatic exposure control device, and the area dose corresponding to the dilution ratio of each contrast agent, Average comparison and correlation analysis were performed on the exposure index. As a result, the CT contrast agent and the MRI contrast agent appeared different in area dose according to the dilution ratio(p<0.05), and as the dilution ratio increased, the area dose increased for CT contrast agent and MRI contrast agent(P<0.05). In each test, the exposure index showed the manufacturer's recommendation of 200-800 EI value, and the exposure index and area dose increased as the area dose increased(p<0.05). In conclusion, CT contrast agent and MRI contrast agent confirmed to increase the area dose by general imaging test using all automatic exposure control device. Therefore, it is considered that it is necessary to perform it after the contrast medium has been excreted sufficiently when using usual imaging test after using the contrast agent in CT and MRI examination.

• Journal of the Korean Society of Radiology
• /
• v.16 no.2
• /
• pp.103-113
• /
• 2022

In this paper, a combined ¹⁸F-FDG(fluorodeoxyglucose) and MNP(magnetic nanoparticles) contrast agent was synthesized using N-(p-maleimidophenyl) isocyanate as the crosslinker for use in simultaneous PET-MRI scans. PET-MRI images were acquired and evaluated before and after injection of the combined contrast imaging agent (¹⁸F-FDG labeled MNP) from a glioma stem cell mouse model. After setting the region of interest (ROI) on each acquired image, the area of the lesion was calculated by segmentation. As a result, the PET image was larger than the MRI. In particular, the simultaneous PET-MRI images showed accurate lesions along with the surrounding soft tissue. The mean and standard deviation values were higher in the MRI images alone than in the PET images or the simultaneous PET-MRI images, regardless of whether the contrast agent was injected. In addition, the simultaneous PET-MRI image values were higher than for the PET images. For PSNR experiments, the original image was PET Image using 18F-FDG, MRI using MNPs, and MRI without contrast medium, and the target image was simultaneous PET-MRI image using 18F-FDG labeled MNPs contrast medium. As a result, all of them appeared significantly, suggesting that the 18F-FDG labeled MNPs contrast medium is useful. Future research is needed to develop an agent that can simultaneously diagnose and treat through SPECT-MRI imaging research that can use various nuclides.

• Archives of Pharmacal Research
• /
• v.29 no.3
• /
• pp.188-190
• /
• 2006

In this study, a newly-synthesized metalloporphyrin, Gd-chlorin (PB Chlorin), was investigated by using a simple tissue phantom to test its efficacy as an MRI contrast agent. This study demonstrated the potential activity of Gd-chlorin as not only a MRI contrast agent, but also as a PDT photosensitizer by using a simple tissue phantom and conducting a very brief MRI experiment.

• Ceramist
• /
• v.22 no.3
• /
• pp.269-280
• /
• 2019

Ceramic layered double hydroxide (LDH) nanohybrids have attracted considerable interest in biomedical science due to their unique structural feature and characteristics in biological condition. Many studies on LDH nanoparticles have been reported in diagnosis applications including magnetic resonance imaging (MRI) contrast agents in order to not only provide better imaging performance through multimodal imaging strategy, but realize therapeutic function which treat cancers in one platform. This review highlights the recent progress in MRI T₁ contrast agent, dual modal imaging system, and MRI-guided drug delivery systems ranging from synthetic method and characterization to evaluation in vitro and in vivo based on the ceramic LDH nanohybrids. Future research directions are also suggested for next-generation bio-imaging contrast agent.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.1 no.2
• /
• pp.130-136
• /
• 2015

We evaluate the influence of MR contrast agent on positron emission tomography (PET) image using phantom, animal and human studies. Phantom consisted of 15 solutions with the mixture of various concentrations of Gd-based MR contrast agent and fixed activity of [$^{18}F$]FDG. Animal study was performed using rabbit and two kinds of MR contrast agents. After injecting contrast agent, CT or MRI scanning was performed at 1, 2, 5, 10, and 20 minutes. PET image was obtained using clinical PET/CT scan, and attenuation correction was performed using the all CT images. The values of HU, PET activity and MRI intensity were obtained from ROIs in each phantom and organ regions. In clinical study, patients (n=20) with breast cancer underwent sequential acquisitions of early [$^{18}F$]FDG PET/CT, MRI and delayed PET/CT. In phantom study, as the concentration increased, the CT attenuation and PET activity also increased. However, there was no relationship between the PET activity and the concentration in the clinical dose range of contrast agent. In animal study, change of PET activity was not significant at all time point of CT scan both MR contrast agents. There was no significant change of HU between early and delayed CT, except for kidney. Early and delayed SUV in tumor and liver showed significant increase and decrease, respectively (P<0.05). Under the condition of most clinical study (< 0.2 mM), MR contrast agent did not influence on PET image quantitation.

• Journal of Magnetics
• /
• v.21 no.2
• /
• pp.281-285
• /
• 2016

The purpose of study was to evaluate SNR and CNR with different contrast agent contents (1.0 mmol/mL gadobutrol and 0.5 mmol/mL gadoterate meglumine) for spin echo (SE) and 3-dimension contrast-enhanced fast field echo (3D CE-FFE) pulse sequences. In this study, we compared the SNR and the CNR between 0.5 mmol/mL gadoterate meglumine and 1.0 mmol/mL gadobutrol according to the concentration of contrast agent in brain MRI. When we compared between SE and 3D CE-FFE pulse sequences, the higher SNR and CNR using 3D CE-FFE pulse sequence can be acquire regardless of contrast agent contents. Also, a statistically significant difference was found for SNR and CNR between all protocols. In conclusion, our results demonstrated that the SNR and CNR have not risen proportionately with contrast agent contents. We hope that these results presented in this paper will contribute to decide contrast agent contents for brain MRI.

• Journal of Magnetics
• /
• v.20 no.3
• /
• pp.302-307
• /
• 2015

The purpose of the study was to identify how isotope and magnetic resonance imaging (MRI) contrast media impact on noise to computed tomography (CT) examination. For the study, divide the phantoms to two groups: 1) saline, saline + different kinds of contrast agent without $^{99m}Tc$ administration; 2) $^{99m}Tc$ administration: saline, saline + different kinds of contrast agent with $^{99m}Tc$ administration. CT contrast agent was used for Iopamidol$^{(R)}$ and Dotarem. And MRI contrast agent was used for Primovist$^{(R)}$ and Gadovist$^{(R)}$. To obtain an image, we used CT scanner. With an obtained image, we set the $1cm^2$ region of interest in the middle of bottle to measure the noise and CT number. As a result, there was no difference in CT number before and after inserting $^{99m}Tc$ into all contrast media including Normal Saline. However, when it comes to Noise, there was a difference before and after inserting $^{99m}Tc$ into every contrast media except MRI contrast media such as Primovist$^{(R)}$ and Gadovist$^{(R)}$.

• Bulletin of the Korean Chemical Society
• /
• v.31 no.5
• /
• pp.1177-1181
• /
• 2010

The synthesis and characterization of gold nanoparticles coated by Gd-chelate (GdL@Au) is described, where L is a conjugate of DTPA (DTPA = diethylenetriamine-N,N,N',N",N"-pentaacetic acid) and 4-aminothiophenol. These particles are obtained by the replacement of citrate from the gold nanoparticle surfaces with gadolinium chelate (GdL). The average size of GdL@Au is 12 nm with a loading of GdL reaching up to $1.4{\times}10^3$ per particles, and they demonstrate very high r1 relaxivity (${\sim}10^4mM^{-1}s^{-1}$) and the r1 relaxivity per [Gd] is as high as $10mM^{-1}s{-1}$. Here, we also describe the use of bimodality of this contrast agent (CA) as a highly efficient CT contrast agent based on gold nanoparticles (GNPs) that overcome the limitations of iodine based contrast agent. The MTT assay performed on this CAs reveals the cytotoxicity as low as that for Omniscan$^{(R)}$ in the concentration range required to obtain intensity enhancement in the in vivo MRI study.

• The Korean Journal of Nuclear Medicine Technology
• /
• v.18 no.1
• /
• pp.19-25
• /
• 2014

Purpose: Integrated PET/MRI has been developed recently has become a lot of help to the point oncologic, neological, cardiological nuclear medicine. By using this PET/MRI, a ${\mu}-map$ is created some special MRI sequence which may be divided parts of the body for attenuation correction. However, because an MRI contrast agent is necessary in order to obtain an more MRI information, we will evaluate to see an effect of SUV on PET image that corrected attenuation by MRI with contrast agent. Materials and Methods: As PET/MRI machine, Biograph mMR (Siemens, Germany) was used. For phantom test, 1mCi $^{18}F-FDG$ was injected in cylinderical uniformity phantom, and then acquire PET data about 10 minutes with VIBE-DIXON, UTE MRI sequence image for attenuation correction. T1 weighted contrast media, 4 cc DOTAREM (GUERBET, FRANCE) was injected in a same phatnom, and then PET data, MRI data were acquired by same methodes. Using this PET, non-contrast MRI and contrast MRI, it was reconstructed attenuation correction PET image, in which we evanuated the difference of SUVs. Additionally, for let a high desity of contrast media, 500 cc 2 plastic bottles were used. We injected $^{18}F-FDG$ with 5 cc DOTAREM in first bottle. At second bottle, only $^{18}F-FDG$ was injected. and then we evaluated a SUVs reconstructed by same methods. For clinical patient study, rectal caner-pancreas cancer patients were selected. we evaluated SUVs of PET image corrected attenuastion by contrast weighted MRI and non-contrast MRI. Results: For a phantom study, although VIBE DIXON MRI signal with contrast media is 433% higher than non-contrast media MRI, the signals intensity of ${\mu}-map$, attenuation corrected PET are same together. In case of high contrast media density, image distortion is appeared on ${\mu}-map$ and PET images. For clinical a patient study, VIBE DIXON MRI signal on lesion portion is increased in 495% by using DOTAREM. But there are no significant differences at ${\mu}-map$, non AC PET, AC-PET image whether using contrast media or not. In case of whole body PET/MRI study, %diff between contras and non contrast MRAC at lung, liver, renal cortex, femoral head, myocardium, bladder, muscle are -4.32%, -2.48%, -8.05%, -3.14%, 2.30%, 1.53%, 6.49% at each other. Conclusion: In integrated PET/MRI, a segmentation ${\mu}-map$ method is used for correcting attenuation of PET signal. although MRI signal for attenuation correciton change by using contrast media, ${\mu}-map$ will not change, and then MRAC PET signal will not change too. Therefore, MRI contrast media dose not affect for attenuation correction PET. As well, not only When we make a flow of PET/MRI protocol, order of PET and MRI sequence dose not matter, but It's possible to compare PET images before and after contrast agent injection.

• Korean Journal of Radiology
• /
• v.25 no.3
• /
• pp.257-266
• /
• 2024

Objective: To investigate molecular and functional consequences of additional exposures to iodine- or gadolinium-based contrast agents within 24 hours from the initial intravenous administration of iodine-based contrast agents through an animal study. Materials and Methods: Fifty-six Sprague-Dawley male rats were equally divided into eight groups: negative control, positive control (PC) with single-dose administration of CT contrast agent, and additional administration of either CT or MR contrast agents 2, 4, or 24 hours from initial CT contrast agent injection. A 12 µL/g of iodinated contrast agent or a 0.47 µL/g of gadolinium-based contrast agent were injected into the tail vein. Serum levels of blood urea nitrogen, creatinine, cystatin C (Cys C), and malondialdehyde (MDA) were measured. mRNA and protein levels of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were evaluated. Results: Levels of serum creatinine (SCr) were significantly higher in repeated CT contrast agent injection groups than in PC (0.21 ± 0.02 mg/dL for PC; 0.40 ± 0.02, 0.34 ± 0.03, and 0.41 ± 0.10 mg/dL for 2-, 4-, and 24-hour interval groups, respectively; P < 0.001). There was no significant difference in the average Cys C and MDA levels between PC and repeated CT contrast agent injection groups (Cys C, P = 0.256-0.362; MDA, P > 0.99). Additional doses of MR contrast agent did not make significant changes compared to PC in SCr (P > 0.99), Cys C (P = 0.262), and MDA (P = 0.139-0.771) levels. mRNA and protein levels of KIM-1 and NGAL were not significantly different among additional CT or MR contrast agent groups (P > 0.05). Conclusion: A sufficient time interval, probably more than 24 hours, between repeated contrast-enhanced CT examinations may be necessary to avoid deterioration in renal function. However, conducting contrast-enhanced MRI on the same day as contrast-enhanced CT may not induce clinically significant kidney injury.